Emerging data indicates that Tarlatamab, a DLL3-targeted therapy, has inferior performance in small cell lung cancer (SCLC) that transformed from EGFR-mutant NSCLC compared to its efficacy in de novo SCLC. This suggests the biological context of transformation impacts treatment response, a critical nuance for this new therapy.

Unlike traditional cytotoxic agents, the DLL3-targeting T-cell engager tarlatumab demonstrates consistent overall survival benefits in third-line SCLC regardless of the patient's chemotherapy-free interval from first-line therapy. This indicates it works via a distinct mechanism that bypasses conventional chemoresistance pathways, representing a new treatment paradigm.

As multiple new drugs like antibody-drug conjugates (ADCs) become available for SCLC, the critical research question will shift from *if* they work to *when* they should be used. Future biomarker strategies must focus on optimizing treatment sequences, considering factors like the drug's target and payload.

In community SCLC care, molecular strategies are not monolithic. Genomic alteration testing (NGS) is ready for immediate use and can identify targets today. In contrast, neuroendocrine subtyping is still investigational and not yet clinically actionable, pending results from research studies.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

Despite its approval, the bispecific T-cell engager tarlatamab sees slower community adoption than prior SCLC drugs. The barrier is the logistical need for inpatient monitoring and specialized supportive care for potential cytokine release syndrome during the first two doses, a new challenge for community practices that suggests a university collaboration model.

Real-world data shows higher rates of cytokine release syndrome (CRS) with tarlatumab than trials reported, especially in sicker patients. Despite this, the drug's risk-benefit profile is often better than chemotherapy for poor-performance patients, sometimes leading to durable, life-changing outcomes where no other options exist.

The necessary delays for screening, eligibility, and logistical setup for clinical trials and novel agents like tarlatamab can take weeks. This makes them unsuitable for patients with rapid, aggressive disease progression, forcing clinicians to rely on older, faster-acting cytotoxic therapies instead.